Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Other Long-Term Liabilities : $-0.00 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Crinetics Pharmaceuticals Other Long-Term Liabilities?

Crinetics Pharmaceuticals's other long-term liabilities for the quarter that ended in Mar. 2024 was $-0.00 Mil.

Crinetics Pharmaceuticals's quarterly other long-term liabilities increased from Sep. 2023 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil) but then declined from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($-0.00 Mil).

Crinetics Pharmaceuticals's annual other long-term liabilities declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Crinetics Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Crinetics Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crinetics Pharmaceuticals Other Long-Term Liabilities Chart

Crinetics Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Crinetics Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Crinetics Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Crinetics Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (NAS:CRNX) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

6Z4:Germany

Address

10222 Barnes Canyon Road, Building No. 2, San Diego, CA, USA, 92121

Website

https://www.crinetics.com

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Executives

Stephen F. Betz	officer: Chief Scientific Officer	10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Dana Pizzuti	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Marc Wilson	officer: See Remarks	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard Scott Struthers	director, officer: See Remarks	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Alan Seth Krasner	officer: Chief Medical Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Vivaldi Coelho Rogerio	director	225 SECOND AVENUE, WALTHAM MA 02451
Jeff E. Knight	officer: Chief Operating Officer	CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Caren Deardorf	director	C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Ajay Madan	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121
Camille L Bedrosian	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003